Banner
Home → Focus

Focus
Healthcare Tops Guns, Economy As Voters' Top Issue Print E-mail
Written by Phil Galewitz | KHN   
Thursday, 18 October 2018 00:00
 
Healthcare has emerged as the top issue for voters headed into the midterm elections, but fewer than half of them say they are hearing a lot from candidates on the issue, according to a new poll released Thursday. Seven in  10 people list health care as "very important" as they make their voting choices, eclipsing the economy and jobs (64 percent), gun policy (60 percent), immigration (55 percent), tax cuts (53 percent) and foreign policy (51 percent). When asked to choose just one issue, nearly a third picked health care, according to the survey by the Kaiser Family Foundation. Still, midterm elections are traditionally a referendum on the president and his party, and that holds true this year as two-thirds of voters say a candidate's support or opposition to President Donald Trump will be a major factor in their voting decision, the poll found. 
 
Read More
 
The Pentagon Wants to Weaponize the Human Brain Print E-mail
Written by FHI's Week in Review   
Monday, 15 October 2018 10:55
 
On Thursday, 10/11/18, The Atlantic posted a fascinating feature article from their print issue coming out next month. A former University of Miami associate professor of biomedical engineering and neuroscience, who now works for the government (Defense Advanced Research Projects Agency, the Pentagon's R&D department), is quoted in the article:

"I would claim to you that these tools <computers and smart phones> are not so smart. And maybe one of the reasons why they're not so smart is because they're not connected to our brains. Maybe if we could hook those devices into our brains, they could have some idea of what our goals are, what our intent is, and what our frustration is."
 
Read more in the current issue of Week in Review>> https://conta.cc/2yEkRjU
 
Last Updated on Tuesday, 18 December 2018 18:22
 
Feds greenlight healthcare mega merger Print E-mail
Written by CNN   
Wednesday, 10 October 2018 00:00
 
David Goldman reports for CNN Business on 10.10.18:
 
A landmark healthcare merger is inches away from the finish line. CVS has gained the US government's approval to buy Aetna. The $69 billion acquisition, announced in December 2017, will drastically remap  the healthcare industry. CVS is a massive drugstore chain and prescription insurer, and Aetna is one of the nation's largest health insurers. It is the largest health insurance deal in history, far exceeding Express Scripts' $29 billion acquisition of Medco in 2012, the last record-holder. To gain the Trump administration's approval, Aetna agreed to spin off its Medicare Part D prescription drug business. The Justice Department settled with CVS and Aetna on Wednesday. Pending a judge's approval of the settlement, the deal will be completed.
 

Last Updated on Friday, 12 October 2018 11:28
 
Physicians' regulatory burden worse than ever despite federal efforts Print E-mail
Written by FHI's Week in Review   
Monday, 08 October 2018 13:19
 
Virgil Dickson reports for Modern Healthcare on 10.4.18:

The CMS has prided itself in recent months on cutting and scaling back providers' regulatory burden, but those efforts have fallen short, according to a new survey by the Medical Group Management Association. An overwhelming majority, or 86%, of respondents reported the overall regulatory burden on their medical practice has increased over the past 12 months.

Read more in the current issue of Week in Review>> https://conta.cc/2E9Jafp
 
Last Updated on Monday, 19 November 2018 18:03
 
DEA Reschedules Epidiolex, Paving the Way to Market Print E-mail
Written by FHI's Week in Review   
Monday, 01 October 2018 00:00
 
Megan Brooks reports for Medscape on 9.27.18:
 
The U.S. Drug Enforcement Administration (DEA) has rescheduled the epilepsy cannabidiol (CBD) drug Epidiolex (GW Pharmaceuticals) from Schedule I to Schedule V, the classification with the lowest degree of restriction - paving the way to market for the cannabis-based treatment, the company has announced. As reported by Medscape Medical News, the U.S. Food and Drug Administration (FDA) approved the drug in June for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged 2 years and older. The approval followed a unanimous thumbs up by an FDA advisory committee in April.
 
Read more in the current issue of Week in Review>> https://conta.cc/2DK21h5
 
Last Updated on Monday, 01 October 2018 17:50
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 10 of 136


Banner
Website design, development, and hosting provided by
Netphiles